抗氧化剂在动脉样硬化中的临床试验:我们正在做正确的事情吗?
1University of California, San Diego, Department of Medicine, La Jolla 92093-0682, USA.
Lancet (London, England)
|July 1, 1995
概括
低密度脂蛋白 (LDL) 的氧化修饰有助于动脉样硬化. 在动物模型中,抗氧化剂显著减缓了这一过程,支持了它们的治疗潜力.
科学领域:
- 心血管研究研究心血管研究
- 氧化压力生物学 氧化压力生物学
- 动脉样硬化病变的发病原因
背景情况:
- 低密度脂蛋白 (LDL) 的氧化修饰是动脉样硬化发展的一个关键假设.
- 氧化后的LDL表现出改变的生物特性,可能会增强异构性.
- 这些属性的精确的体内机制和相对重要性仍在研究中.
研究的目的:
- 评估LDL氧化修饰在动脉样硬化进展中的作用.
- 评估抗氧化剂在缓解实验性动脉样硬化的有效性.
主要方法:
- 对体外发现和动脉样硬化的动物模型的审查.
- 分析了18项已发表的研究,研究了各种动物模型中的抗氧化剂干预 (例如,LDL受体缺乏的子,胆固醇养的子,非人类灵长类动物).
主要成果:
- 在18项研究中,有13项显示出强烈积极的结果,病变进展减少了50-80%.
- 两项研究产生了微弱的积极结果,而三项则是负面的.
- 四种不同的抗氧化物化合物 (普罗布科尔,BHT,DPPD,维生素E) 显示出有效性.
结论:
- 在多种实验模型中,抗氧化剂可以有效地减缓动脉动脉的过程.
- 不同抗氧化剂之间一致的结果支持它们的作用机制通过抗氧化剂潜力.
- 需要进一步的研究来阐明氧化LDL的异原性精确的体内机制.
相关概念视频
Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Coronary Artery Disease I: Introduction
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Coronary Artery Disease IV: Preventive Measures
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...


